Robert Bosch Gesellschaft für Medizinische Forschung mbH — Stuttgart, Baden-Wurttemberg

Public research footprint of Robert Bosch Gesellschaft für Medizinische Forschung mbH, compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Most-studied conditions

Interstitial Lung Diseases · Anthracycline-induced Cardiotoxicity · Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology · Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology

Recently updated registry entries

NCT07280585 — STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease (Recruiting)
NCT07064473 — EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin… (Recruiting)
NCT06926660 — A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Robert Bosch Gesellschaft für Medizinische Forschung mbH?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 04, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.